NCT06125080招募中2 期
The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study
Huihua Xiong1 个研究点 分布在 1 个国家目标入组 78 人开始时间: 2023年10月30日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 78
- 试验地点
- 1
- 主要终点
- Objective Response Rate, ORR
研究概览
简要总结
This is a multicenter, open-label, single-arm clinical study designed to evaluate the safety and efficacy of Utidelone plus Tirelizumab and Bevacizumab for advanced or metastatic triple-negative breast cancer (TNBC).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients voluntarily participated in the study, signed the informed consent, and had good compliance; Female patients aged 18-70; TNBC confirmed by histology or cytology. Triple negative is defined as <1% expression of estrogen receptor (ER) and progesterone receptor (PR), and negative in situ hybridization expression of human epidermal growth factor receptor 2 (HER2). Unresectable locally advanced or metastatic TNBC failed or relapsed after treatment with at least one line of standard chemotherapy regimens (taxanes and/or anthracyclines); Patients should have at least one measurable lesion (RECIST 1.1); ECOG PS 0 or 1; Expected survival ≥12 weeks; Blood test (without blood transfusion within 14 days)
- •Neutrophil absolute value ≥1.5×109/L, platelet ≥100×109/L, hemoglobin concentration ≥9g/dL);
- •Liver function test (aspartate aminotransferase and glutamic aminotransferase ≤2.5×ULN, bilirubin ≤1.5×ULN; In the presence of liver metastasis, AST and ALT≤5×ULN);
- •Renal function (serum creatinine ≤1.5×ULN, or creatinine clearance (CCr)≥60ml/min);
- •Coagulation, International standardized ratio (INR) ≤1.5, prothrombin time (PT) and activated partial thrombin time (APTT) ≤1.5×ULN;
- •Thyroid function, thyroid stimulating hormone (TSH) ≤ upper limit of normal (ULN); If abnormal, FT3 and FT4 levels should be examined, and normal FT3 and FT4 levels can be included. Women of reproductive age must undergo a negative serum pregnancy test within 14 days prior to treatment and be willing to use medically approved effective birth control (e.g., intrauterine devices, contraceptives or condoms) during the study period and within 3 months after the last study drug use.
排除标准
- •During the first 4 weeks of treatment, receive the following treatments:
- •including but not limited to surgery, chemotherapy, radical radiotherapy, biotargeted therapy, immunotherapy, and other investigational drugs; Previous treatment with anti-VEGF /VEGFR targeting drugs, such as Bevacizumab; Or have previously received the following therapies: anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or synergistic inhibition of T cell receptors in response to another stimulus (including but not limited to CTLA-4, OX-40, LAG-3, CD137, etc.); Immunosuppressive drugs have been administered in the 14 days prior to initiation of treatment, but do not include nasal and inhaled corticosteroid hormones or physiological doses of systemic steroid hormones (i.e., the daily dose of prednisolone does not exceed 10 mg or the equivalent physiological dose of another corticosteroid); History of any active autoimmune disease or autoimmune disease (including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitaritis, vasculitis, nephritis, hyperthyroidism, hypothyroidism; Subjects with vitiligo or asthma may have complete remission in childhood and do not currently require medical intervention, or have a history of allotransplantation or allohematopoietic stem cell transplantation); Have high blood pressure that is not well controlled by antihypertensive medications (systolic blood pressure ≥140 mmHg or diastolic blood pressure
- •≥90 mmHg) Urine routine indicated urine protein ≥2+, and 24 hours urine protein quantity >1.0g; Obvious clinical bleeding symptoms or obvious bleeding tendency (bleeding > 30 mL within 3 months, hematemesis, black feces, blood in stool), hemoptysis (fresh blood > 5 mL within 4 weeks) within 3 months prior to treatment. Or treatment of venous/venous thrombosis events occurring within the preceding 6 months, such as cerebrovascular accidents (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism; Long-term anticoagulant therapy with warfarin or heparin, or long-term antiplatelet therapy (aspirin ≥300 mg/day or clopidogrel ≥75 mg/day) is required; Active heart disease, including myocardial infarction, severe/unstable angina, occurs 6 months before treatment. Left ventricular ejection fraction < 50% by echocardiography and poor arrhythmia control (including QTcF interval,> 470 ms in women); The patient has had other malignancies (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix) within the previous 3 years or at the same time. Known allergy to the study drug or any of its excipients, or severe allergic reaction to other monoclonal antibodies; Active or uncontrolled severe infection;
- •Known human immunodeficiency virus (HIV) infection;
- •A known history of clinically significant liver disease, including viral hepatitis [active HBV infection, i.e., HBV DNA positive (>1×104 copies
- •/mL or >2000 IU/ml) must be excluded for a known hepatitis B virus (HBV) carrier;
- •Known hepatitis C virus infection (HCV) and HCV RNA positive (>1×103 copies /mL), or other hepatitis, cirrhosis]; Any other medical condition, clinically significant metabolic abnormality, physical abnormality or laboratory abnormality, which, in the investigator's judgment, the patient has a medical condition or condition that is reasonably suspected to be unsuitable for the use of the study drug (such as the presence of epileptic seizures requiring treatment), or which would interfere with the interpretation of the study results, or place the patient at high risk; The patients considered by the investigators to be unsuitable for inclusion in this study.
研究组 & 干预措施
Utidelone+Tirelizumab+Bevacizumab
Experimental
干预措施: Bevacizumab (Drug)
Utidelone+Tirelizumab+Bevacizumab
Experimental
干预措施: Utidelone (Drug)
Utidelone+Tirelizumab+Bevacizumab
Experimental
干预措施: Tirelizumab (Drug)
结局指标
主要结局
Objective Response Rate, ORR
时间窗: approximately 1 years
The proportion of patients with complete response or partial response, using RECIST v1.1.
次要结局
- Safety, AEs(approximately 2 years)
- Disease Control Rate, DCR(approximately 1 years)
- Overall Survival, OS(approximately 2 years)
- Progression-free Survival, PFS(approximately 1 years)
研究者
Huihua Xiong
Professor
Tongji Hospital
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal CancerEsophageal CancerNCT05866510Peking University47
招募中
2 期
Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant TherapyTriple Negative Breast NeoplasmsNCT06385990Hunan Cancer Hospital53
招募中
2 期
Utidelone Injection Combined With Gemcitabine in First-line Chemotherapy for Unresectable Advanced Pancreatic CancerPancreatic NeoplasmsNCT05795920Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine92
招募中
2 期
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain MetastasesNCT06764940Biostar Pharma, Inc.120
招募中
3 期
Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast CancerBreast CancerNCT05673629Beijing Biostar Pharmaceuticals Co., Ltd.552